Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Key Highlights
- ➤Q3 revenue $33.5 million, up 68% year over year
- ➤2026 revenue guidance raised to $121 million-$123 million
- ➤UK Biobank selected Alamar to profile 80,000 samples
- ➤GSK collaboration launched for a 60,000-sample precision-medicine study
- ➤Tod White to retire as president at 2026 year-end
Expert Statements
Yuling Luo, Founder, CEO, and chair of Alamar Biosciences
“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time,”
Yuling Luo, Founder, CEO and chair of Alamar Biosciences
“Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Yuling Luo, Founder, CEO and chair of Alamar Biosciences
“Tod has been an outstanding partner and leader during a pivotal period for Alamar,”
Yuling Luo, Founder, CEO and chair of Alamar Biosciences
“He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”
Tod White, President of Alamar Biosciences
“It has been a privilege to work alongside this exceptional team,”
Tod White, President of Alamar Biosciences
“Their talent, dedication, and belief in what precision proteomics can do to improve human health have driven everything we have accomplished. Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.”
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended September 30, 2026.
Recent Highlights * Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025 * Selected by UK Biobank to profile 80,000 samples for study targeting earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions * Launched a strategic scientific collaboration with GSK for large-scale 60,000-sample study to advance precision medicine across respiratory, liver, kidney, neurological and autoimmune conditions * Announced publication of first longitudinal treatment response for Alzheimer’s disease using NULISA platform published in Lancet Neurology * Raising full-year 2026 revenue guidance to $121 million to $123 million, representing growth of 64% at the midpoint of the range as compared to 2025 “Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time,” said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. “Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Get started
Create a free account to read the full story.